NCT04380038View on ClinicalTrials.gov

Viral Infection in Asthma (VIA) Study

PHASE4RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Asthma

Interventions

DRUG

Dupilumab Injectable Product

Nasal inoculation, single dose 300 TCID50 in 1ml.

Trial Locations (1)

22908

RECRUITING

University of Virginia, Charlottesville

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University of Virginia

OTHER